Hb Wealth Management Adds $1M in Bristol-Myers Squibb Company ($BMY)
The firm added 22,867 shares, lifting its holdings to 109,993 shares as of the latest quarter.
Key Points
- Hb Wealth Management boosted its stake in Bristol-Myers Squibb by 26.2%, adding 22,867 shares to a total of 109,993 shares.
- Bristol-Myers Squibb's market cap is $117.46 billion, with a P/E ratio of 16.1 and a beta of 0.238.
- Insider trades included Julia Haller's purchase of 20,460 shares on June 15, 2026, and analysts have set price targets up to $75.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hb Wealth Management increased its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 26.2%, as revealed in its latest SEC filing. The firm added 22,867 shares, bringing its total to 109,993 shares valued at approximately $6.44 million as of the reporting period.
Hb Wealth Management vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Hb Wealth Management's Bristol-Myers Squibb Position
Hb Wealth Management boosted its holdings in Bristol-Myers Squibb by 26.2%, adding 22,867 shares to its previous count of 87,126 shares. This brings its total holdings to 109,993 shares, valued at about $6.44 million.
Other Institutional Activity in Bristol-Myers Squibb
Among other institutional investors, BlackRock, Inc. trimmed its holdings by 5,142,518 shares, ending with 171,682,888 shares worth about $10.41 billion, marking a 2.9% decrease. Vanguard Capital Management LLC opened a new position with 132,320,240 shares valued at $8.03 billion. State Street Corp added 584,476 shares, increasing its stake by 0.6% to 98,564,914 shares, valued at $5.98 billion. JPMorgan Chase & Co raised its holdings by 17,107,541 shares, a 22.7% increase, to 92,475,194 shares worth $5.52 billion.
Bristol-Myers Squibb Company Stock Down 13.5%
Shares of NYSE:BMY traded near $58.56 on Tuesday. Bristol-Myers Squibb has a market cap of $117.46 billion and a P/E ratio of 16.1. The stock has a 52-week range between $42.52 and $62.89. The 50-day moving average is $57.09, and the 200-day moving average is $53.80. The company maintains a current ratio of 1.42 and a quick ratio of 1.178, with a debt-to-equity ratio of 230.967.
$BMY stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Bristol-Myers Squibb reported revenue of $48.48 billion, with a revenue growth of 2.6%. The company's net margin stands at 15.0%, and it has a return on equity of 38.7%. The next earnings report is scheduled for July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
Analyst view held steady after the report.
-
EPS & revenue
EPS beat estimates by 10.4%. Revenue beat estimates by 4.3%.
-
Profit surprise
EBITDA missed by 13 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
- Analyst signal
-
Earnings quality
Gross margin up 4.7 points. Operating margin down 3.0 points. Positive free cash flow.
Earnings Call Summary
Bristol delivered a solid first quarter with revenue of 11.5 billion dollars, up 1 percent year over year, and earnings per share of 1.58 dollars, beating Wall Street by 10 percent. The growth portfolio grew 9 percent, led by strong performances from Eliquis at 4.1 billion dollars and Breyanzi up 53 percent. Management highlighted progress across pipeline programs including positive data for Pumitamig and upcoming late-year readouts for Factor XI inhibitor Milvexian and Cobenfy in Alzheimer's disease psychosis.
Guidance Bristol reaffirmed its 2026 financial targets and said the company is tracking toward the upper end of guidance. The management team noted strong momentum in the growth portfolio and multiple clinical readouts expected in the second half of the year, including Milvexian in atrial fibrillation and Cobenfy in Alzheimer's psychosis.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Dividend
The company pays an annual dividend of $2.52, yielding 4.38%. The dividend payout ratio is 70.03%.
Insider Buying and Selling at Bristol-Myers Squibb Company
On June 15, 2026, Julia Haller purchased 20,460 shares at an average price of $53.76. On the same day, she also sold 20,460 shares, though the price was not specified. Wendy Short, EVP of Corporate Affairs, sold 8,040 shares on June 3, 2026, and bought the same amount back, with 3,876 shares sold at $54.72.
Analysts Set New Price Targets
On April 9, 2026, B of A Securities maintained a buy rating with a $67 price target. Cantor Fitzgerald kept a hold rating with a $54 target on April 8, 2026. HSBC maintained a hold rating with a $60 target on March 17, 2026. The consensus among 25 analysts is a target mean price of $63.08.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company, headquartered in Princeton, New Jersey, is a global biopharmaceutical company. It develops and sells products for oncology, hematology, immunology, and cardiovascular diseases. The company, led by CEO Dr. Christopher S. Boerner, employs approximately 32,500 people and was founded in 1887.
Bottom Line
Hb Wealth Management's increased stake in Bristol-Myers Squibb reflects a growing confidence in the company's prospects. While the 13F filing provides a snapshot of past holdings, it doesn't necessarily indicate current positions. Investors keep a close eye on such filings to gauge institutional sentiment and potential market impact.
Get Bristol-Myers Squibb Company alerts
New 13F filings, insider trades, and analyst moves on $BMY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.